Cervix Cancer in Sub-Saharan Africa: An Assessment of Cervical Cancer Management.
Journal
JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
6
8
2021
Statut:
ppublish
Résumé
Underdeveloped nations carry the burden of most cervical cancer, yet access to adequate treatment can be challenging. This report assesses the current management of cervical cancer in sub-Saharan Africa to better understand the needs of underdeveloped nations in managing cervical cancer. A pre- and postsurvey was sent to all centers participating in the Cervical Cancer Research Network's 4th annual symposium. The pre- and postsurvey evaluated human papillomavirus and HIV screening, resources available for workup and/or treatment, treatment logistics, outcomes, and enrollment on clinical trials. Descriptive analyses were performed on survey responses. Twenty-nine centers from 12 sub-Saharan countries saw approximately 300 new cases of cervical cancer yearly. Of the countries surveyed, 55% of countries had a human papillomavirus vaccination program and 30% (range, 0%-65%) of women in each region were estimated to have participated in a cervical cancer screening program. In the workup of patients, 43% of centers had the ability to obtain a positron emission tomography and computed tomography scan and 79% had magnetic resonance imaging capabilities. When performing surgery, 88% of those centers had a surgeon with an expertise in performing oncological surgeries. Radiation therapy was available at 96% of the centers surveyed, and chemotherapy was available in 86% of centers. Clinical trials were open at 4% of centers. There have been significant advancements being made in screening, workup, and management of patients with cervical cancer in sub-Saharan Africa; yet, improvement is still needed. Enrollment in clinical trials remains a struggle. Participants would like to enroll patients on clinical trials with Cervical Cancer Research Network's continuous support.
Identifiants
pubmed: 33529076
doi: 10.1200/GO.20.00079
pmc: PMC8081497
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-182Subventions
Organisme : NCI NIH HHS
ID : K08 CA228631
Pays : United States
Références
J Infect Dis. 2004 Oct 15;190(8):1413-21
pubmed: 15378433
Gynecol Oncol Rep. 2016 Nov 25;19:5-9
pubmed: 28004030
J Clin Oncol. 2000 Apr;18(8):1606-13
pubmed: 10764420
Vaccine. 2015 May 7;33 Suppl 1:A167-73
pubmed: 25919157
Vaccines (Basel). 2018 Sep 08;6(3):
pubmed: 30205561
Gynecol Oncol. 2016 Sep;142(3):413-9
pubmed: 27178725
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Semin Radiat Oncol. 2017 Apr;27(2):184-188
pubmed: 28325246
Clin Transl Oncol. 2011 Jul;13(7):431-3
pubmed: 21775268
J Glob Oncol. 2017 Feb 8;3(5):666-670
pubmed: 29094103
J Clin Oncol. 2019 Nov 20;37(33):3124-3131
pubmed: 31449470
Lancet Oncol. 2015 Sep;16(10):1153-86
pubmed: 26419354
Gynecol Oncol. 1999 May;73(2):177-83
pubmed: 10329031
Vaccine. 2015 May 7;33 Suppl 1:A174-81
pubmed: 25919158